Deaths related to pulmonary embolism and cardiovascular events before and during the 2020 COVID-19 pandemic: An epidemiological analysis of data from an Italian high-risk area.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
04 2022
Historique:
received: 05 01 2022
revised: 07 02 2022
accepted: 08 02 2022
pubmed: 28 2 2022
medline: 18 3 2022
entrez: 27 2 2022
Statut: ppublish

Résumé

Pulmonary embolism is a known complication of coronavirus disease 2019 (COVID-19). Epidemiological population data focusing on pulmonary embolism-related mortality is limited. Veneto is a region in Northern Italy counting 4,879,133 inhabitants in 2020. All ICD-10 codes from death certificates (1st January 2018 to 31st December 2020) were examined. Comparisons were made between 2020 (COVID-19 outbreak) and the average of the two-year period 2018-2019. All-cause, COVID-19-related and the following cardiovascular deaths have been studied: pulmonary embolism, hypertensive disease, ischemic heart disease, atrial fibrillation/flutter, and cerebrovascular diseases. In 2020, a total of 56,412 deaths were recorded, corresponding to a 16% (n = 7806) increase compared to the period 2018-2019. The relative percentage increase during the so-called first and second waves was 19% and 44%, respectively. Of 7806 excess deaths, COVID-19 codes were reported in 90% of death certificates. The percentage increase in pulmonary embolism-related deaths was 27% (95%CI 19-35%), 1018 deaths during the year 2020, compared to 804 mean annual deaths in the period 2018-2019. This was more evident among men, who experience an absolute increase of 147 deaths (+45%), than in women (+67 deaths; +14%). The increase was primarily driven by deaths recorded during the second wave (+91% in October-December). An excess of deaths, particularly among men and during the second wave, was also observed for other cardiovascular diseases, notably hypertensive disease, atrial fibrillation, cerebrovascular disease, and ischemic heart disease. We observed a considerable increase of all-cause mortality during the year 2020. This was mainly driven by COVID-19 and its complications. The relative increase in the number of pulmonary embolism-related deaths was more prominent during the second wave, suggesting a possible underdiagnosis during the first wave.

Sections du résumé

BACKGROUND
Pulmonary embolism is a known complication of coronavirus disease 2019 (COVID-19). Epidemiological population data focusing on pulmonary embolism-related mortality is limited.
METHODS
Veneto is a region in Northern Italy counting 4,879,133 inhabitants in 2020. All ICD-10 codes from death certificates (1st January 2018 to 31st December 2020) were examined. Comparisons were made between 2020 (COVID-19 outbreak) and the average of the two-year period 2018-2019. All-cause, COVID-19-related and the following cardiovascular deaths have been studied: pulmonary embolism, hypertensive disease, ischemic heart disease, atrial fibrillation/flutter, and cerebrovascular diseases.
RESULTS
In 2020, a total of 56,412 deaths were recorded, corresponding to a 16% (n = 7806) increase compared to the period 2018-2019. The relative percentage increase during the so-called first and second waves was 19% and 44%, respectively. Of 7806 excess deaths, COVID-19 codes were reported in 90% of death certificates. The percentage increase in pulmonary embolism-related deaths was 27% (95%CI 19-35%), 1018 deaths during the year 2020, compared to 804 mean annual deaths in the period 2018-2019. This was more evident among men, who experience an absolute increase of 147 deaths (+45%), than in women (+67 deaths; +14%). The increase was primarily driven by deaths recorded during the second wave (+91% in October-December). An excess of deaths, particularly among men and during the second wave, was also observed for other cardiovascular diseases, notably hypertensive disease, atrial fibrillation, cerebrovascular disease, and ischemic heart disease.
CONCLUSIONS
We observed a considerable increase of all-cause mortality during the year 2020. This was mainly driven by COVID-19 and its complications. The relative increase in the number of pulmonary embolism-related deaths was more prominent during the second wave, suggesting a possible underdiagnosis during the first wave.

Identifiants

pubmed: 35219931
pii: S0049-3848(22)00045-7
doi: 10.1016/j.thromres.2022.02.008
pmc: PMC8858636
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

44-50

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

Euro Surveill. 2020 Nov;25(47):
pubmed: 33243356
Thromb Res. 2021 Jul;203:82-84
pubmed: 33975205
Eur J Epidemiol. 2021 Feb;36(2):213-218
pubmed: 33495860
Eur Heart J. 2022 Mar 14;43(11):1141-1153
pubmed: 34632491
Prim Care Diabetes. 2021 Aug;15(4):653-681
pubmed: 34083122
Glob Heart. 2022 Feb 21;17(1):11
pubmed: 35342694
J Thromb Thrombolysis. 2021 Jul;52(1):92-94
pubmed: 33175288
JAMA. 2020 Nov 24;324(20):2100-2102
pubmed: 33044514
Lancet. 2020 May 30;395(10238):1715-1725
pubmed: 32405103
Res Pract Thromb Haemost. 2021 Dec 17;5(8):e12638
pubmed: 34977448
N Engl J Med. 2020 Jul 23;383(4):400-401
pubmed: 32383831
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Thromb Res. 2021 Mar;199:143-148
pubmed: 33535120
Res Pract Thromb Haemost. 2020 Jun 25;4(5):835-841
pubmed: 32685892
Thromb Res. 2022 Jan;209:94-98
pubmed: 34896917
Lancet. 2022 Jan 1;399(10319):50-59
pubmed: 34921756
Eur J Intern Med. 2020 Dec;82:29-37
pubmed: 32958372
Soc Sci Med. 2020 Aug;258:113101
pubmed: 32521411
Int J Epidemiol. 2021 Jan 23;49(6):1909-1917
pubmed: 33053172
Thromb Res. 2021 Jun;202:17-23
pubmed: 33711754
Thromb Res. 2020 Sep;193:86-89
pubmed: 32531548
Prev Med. 2021 Dec;153:106818
pubmed: 34599924
N Engl J Med. 2020 Aug 13;383(7):691-693
pubmed: 32427432
Lancet Respir Med. 2020 Mar;8(3):277-287
pubmed: 31615719
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
Eur J Prev Cardiol. 2021 Dec 20;28(14):1599-1609
pubmed: 33611594
Respir Res. 2021 Nov 20;22(1):298
pubmed: 34801044
Am J Public Health. 2021 Aug;111(8):1518-1522
pubmed: 34185569
J Am Coll Cardiol. 2021 Jan 19;77(2):159-169
pubmed: 33446309
BMJ. 2021 May 19;373:n1137
pubmed: 34011491
Thromb Haemost. 2022 May;122(5):789-795
pubmed: 34255341
JAMA. 2021 Jul 6;326(1):82-84
pubmed: 34076670
BMC Public Health. 2020 Aug 14;20(1):1238
pubmed: 32795276
Viruses. 2022 Jan 28;14(2):
pubmed: 35215869
Eur Heart J Qual Care Clin Outcomes. 2021 May 3;7(3):238-246
pubmed: 32730620

Auteurs

Davide Voci (D)

Department of Angiology, University Hospital Zurich, Zurich, Switzerland.

Ugo Fedeli (U)

Epidemiological Department, Azienda Zero, Veneto Region, Padua, Italy.

Ioannis T Farmakis (IT)

Center for Thrombosis and Hemostasis, Johannes Gutenberg University Mainz, Mainz, Germany.

Lukas Hobohm (L)

Center for Thrombosis and Hemostasis, Johannes Gutenberg University Mainz, Mainz, Germany; Department of Cardiology, Cardiology I, Johannes Gutenberg University Mainz, Mainz, Germany.

Karsten Keller (K)

Center for Thrombosis and Hemostasis, Johannes Gutenberg University Mainz, Mainz, Germany; Department of Cardiology, Cardiology I, Johannes Gutenberg University Mainz, Mainz, Germany.

Luca Valerio (L)

Center for Thrombosis and Hemostasis, Johannes Gutenberg University Mainz, Mainz, Germany.

Elena Schievano (E)

Epidemiological Department, Azienda Zero, Veneto Region, Padua, Italy.

Claudio Barbiellini Amidei (C)

Department of Cardiologic, Vascular and Thoracic Sciences and Public Health, University of Padova, Padova, Italy.

Stavros V Konstantinides (SV)

Center for Thrombosis and Hemostasis, Johannes Gutenberg University Mainz, Mainz, Germany; Department of Cardiology, Democritus University of Thrace, Greece.

Nils Kucher (N)

Department of Angiology, University Hospital Zurich, Zurich, Switzerland.

Stefano Barco (S)

Department of Angiology, University Hospital Zurich, Zurich, Switzerland; Center for Thrombosis and Hemostasis, Johannes Gutenberg University Mainz, Mainz, Germany. Electronic address: stefano.barco@usz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH